- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01844687
Laboratory Study of Cannabidiol on the Effects of Smoked Marijuana
November 21, 2019 updated by: National Institute on Drug Abuse (NIDA)
Laboratory Study of the Influence of Oral Cannabidiol on the Subjective, Reinforcing and Cardiovascular Effects of Smoked Marijuana
The objective of this study is to assess the effects of oral cannabidiol (CBD; 0, 200, 400, 800 mg) on smoked marijuana's (0, 5.6% THC) subjective, reinforcing, cognitive, and cardiovascular effects.
This experiment is expected to reveal CBD's intrinsic effects when combined with placebo marijuana, as well as its ability to modulate the behavioral effects of active marijuana.
Study Overview
Detailed Description
Marijuana contains many chemicals called cannabinoids.
The ingredient mainly responsible for marijuana's psychoactive effects is called THC (delta-9-tetrahydrocannabinol.
Another cannabinoid in marijuana is cannabidiol.
It is found in smaller quantities than THC.
Cannabidiol is thought to interfere with the effects of THC.
Therefore, synthetically produced cannabidiol is given to healthy marijuana users in this study to test its capability to reduce the high of THC and, thereby, help to relieve addiction to marijuana.
Study Type
Interventional
Enrollment (Actual)
50
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Kentucky
-
Lexington, Kentucky, United States, 40513
- University of Kentucky, Straus Behavioral Research Bldg., 515 Oldham Ct.
-
-
New York
-
New York, New York, United States, 10032
- Marijuana Outpatient Lab 1051 Riverside Dr. Unit #120
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Center for Drug and Alcohol Programs, Room 459 North, 67 President St.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 48 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Adults between the ages of 18 and 50.
- Current marijuana use: Minimum of four times per week, 0.5 joints per occasion during the preceding 4 weeks.
- Able to perform study procedures
- Women practicing an effective form of birth control
Exclusion Criteria:
- Female subjects who are currently pregnant or breastfeeding.
- Current, repeated illicit drug use other than marijuana
- Presence of significant medical illness
- History of heart disease
- Request for drug treatment
- Current parole or probation
- Recent history of significant violent behavior
- Major psychiatric disorder
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Active marijuana (MJ) with 0 mg CBD
Active MJ cigarettes contain 5.30% THC
|
Each subject in the study was tested on eight days, each day receiving a different combination of active/inactive cannabis cigarettes plus 0, 200, 400 or 800 mg of CBD in random order.
Cigarettes contained either 0.01 or 5.30% THC.
At each visit, participants were given four gelatin capsules containing lactose and 0 or 200 mg of CBD in combinations to achieve scheduled dose level.
Other Names:
|
Other: Active MJ with 200 mg CBD
Active MJ cigarettes contain 5.30% THC
|
Each subject in the study was tested on eight days, each day receiving a different combination of active/inactive cannabis cigarettes plus 0, 200, 400 or 800 mg of CBD in random order.
Cigarettes contained either 0.01 or 5.30% THC.
At each visit, participants were given four gelatin capsules containing lactose and 0 or 200 mg of CBD in combinations to achieve scheduled dose level.
Other Names:
|
Other: Active MJ with 400 mg CBD
Active MJ cigarettes contain 5.30% THC
|
Each subject in the study was tested on eight days, each day receiving a different combination of active/inactive cannabis cigarettes plus 0, 200, 400 or 800 mg of CBD in random order.
Cigarettes contained either 0.01 or 5.30% THC.
At each visit, participants were given four gelatin capsules containing lactose and 0 or 200 mg of CBD in combinations to achieve scheduled dose level.
Other Names:
|
Other: Active MJ with 800 mg CBD
Active MJ cigarettes contain 5.30% THC
|
Each subject in the study was tested on eight days, each day receiving a different combination of active/inactive cannabis cigarettes plus 0, 200, 400 or 800 mg of CBD in random order.
Cigarettes contained either 0.01 or 5.30% THC.
At each visit, participants were given four gelatin capsules containing lactose and 0 or 200 mg of CBD in combinations to achieve scheduled dose level.
Other Names:
|
Other: Inactive MJ with 0 mg CBD
Inactive MJ cigarettes contain 0.01% THC
|
Each subject in the study was tested on eight days, each day receiving a different combination of active/inactive cannabis cigarettes plus 0, 200, 400 or 800 mg of CBD in random order.
Cigarettes contained either 0.01 or 5.30% THC.
At each visit, participants were given four gelatin capsules containing lactose and 0 or 200 mg of CBD in combinations to achieve scheduled dose level.
Other Names:
|
Other: Inactive MJ with 200 mg CBD
Inactive MJ cigarettes contain 0.01% THC
|
Each subject in the study was tested on eight days, each day receiving a different combination of active/inactive cannabis cigarettes plus 0, 200, 400 or 800 mg of CBD in random order.
Cigarettes contained either 0.01 or 5.30% THC.
At each visit, participants were given four gelatin capsules containing lactose and 0 or 200 mg of CBD in combinations to achieve scheduled dose level.
Other Names:
|
Other: Inactive MJ with 400 mg CBD
Inactive MJ cigarettes contain 0.01% THC
|
Each subject in the study was tested on eight days, each day receiving a different combination of active/inactive cannabis cigarettes plus 0, 200, 400 or 800 mg of CBD in random order.
Cigarettes contained either 0.01 or 5.30% THC.
At each visit, participants were given four gelatin capsules containing lactose and 0 or 200 mg of CBD in combinations to achieve scheduled dose level.
Other Names:
|
Other: Inactive MJ with 800 mg CBD
Inactive MJ cigarettes contain 0.01% THC
|
Each subject in the study was tested on eight days, each day receiving a different combination of active/inactive cannabis cigarettes plus 0, 200, 400 or 800 mg of CBD in random order.
Cigarettes contained either 0.01 or 5.30% THC.
At each visit, participants were given four gelatin capsules containing lactose and 0 or 200 mg of CBD in combinations to achieve scheduled dose level.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mood Scale - Subscale 'Feeling High'
Time Frame: two hours before and after marijuana cigarette smoking
|
Participants rated how much they felt having a "high" feeling from smoked marijuana using a visual analog scale 1-100 mm, 1 (Not at all) - 100 (extremely).
|
two hours before and after marijuana cigarette smoking
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Marijuana Rating Form - Like
Time Frame: 15 - 120 minutes after marijuana cigarette smoking
|
Participants rated how much they liked the effects of smoked marijuana using a visual analog scale 1-100 mm, 1=least, 100= most
|
15 - 120 minutes after marijuana cigarette smoking
|
Marijuana Rating Form - Strength
Time Frame: 15 - 120 minutes after marijuana cigarette smoking
|
Participants rated the strength effects of smoked marijuana using a visual analog scale 1-100 mm, 1=least, 100= most
|
15 - 120 minutes after marijuana cigarette smoking
|
Optional Additional Puffs of MJ Cigarette
Time Frame: 150 to 250 minutes after first marijuana cigarette was smoked earlier in the day
|
Participants were allowed to choose to take or reject additional puffs of the same type of MJ cigarette they smoked earlier in the day.
Counts of participants choosing to take additional puffs are reported.
|
150 to 250 minutes after first marijuana cigarette was smoked earlier in the day
|
Number of Optional Puffs of MJ Cigarette Taken
Time Frame: 150 to 160 minutes after first marijuana cigarette was smoked earlier in the day
|
Mean number of puffs taken by those participants who chose to take additional puffs.
|
150 to 160 minutes after first marijuana cigarette was smoked earlier in the day
|
Heart Rate
Time Frame: 120 minutes before and 150 minutes after marijuana cigarette smoking
|
Heart rate measured at 10 time points, 4 before and 6 after smoking cannabis.
|
120 minutes before and 150 minutes after marijuana cigarette smoking
|
Plasma Concentration of CBD
Time Frame: 6 hours
|
Plasma concentrations of cannabidiol were measured at six time points after oral administration of four 200 mg capsules of CBD.
|
6 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Margaret Haney, M.D., New York State Psychiatric Institute
- Study Director: Robert J Malcolm, M.D., Medical University of South Carolina
- Study Director: Sharon Walsh, Ph.D., University of Kentucky
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2013
Primary Completion (Actual)
October 1, 2014
Study Completion (Actual)
October 1, 2014
Study Registration Dates
First Submitted
April 29, 2013
First Submitted That Met QC Criteria
April 29, 2013
First Posted (Estimate)
May 1, 2013
Study Record Updates
Last Update Posted (Actual)
December 9, 2019
Last Update Submitted That Met QC Criteria
November 21, 2019
Last Verified
April 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Study Number CBD-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Smoking, Marijuana
-
Western University, CanadaRecruitingCannabis Use | Marijuana Smoking | Cannabis Smoking | Marijuana UsageCanada
-
RANDNational Institute on Alcohol Abuse and Alcoholism (NIAAA)CompletedAlcohol Drinking | Cigarette Smoking | Marijuana SmokingUnited States
-
Yale UniversityCompleted
-
Yale UniversityCompleted
-
Pacific Institute for Research and EvaluationCompletedSmoking | Alcohol Drinking | Marijuana SmokingUnited States
-
Brown UniversityCompleted
-
New York State Psychiatric InstituteNational Institute on Drug Abuse (NIDA); Research Foundation for Mental Hygiene...CompletedMarijuana SmokingUnited States
-
Johns Hopkins UniversityNational Institute on Drug Abuse (NIDA)Completed
-
State University of New York at BuffaloCompleted
-
New York State Psychiatric InstituteNational Institute on Drug Abuse (NIDA); Research Foundation for Mental Hygiene...Completed
Clinical Trials on CBD
-
Hartford HospitalYale UniversityActive, not recruiting
-
Johns Hopkins UniversityCultivate BiologicsCompleted
-
University of Texas at AustinWay West Wellness; SunFlora.IncSuspendedAnger | Sleep Disturbance | Anxiety Depression | Substance Abuse | Alcohol Abuse | Stress ReactionUnited States
-
Universidad de GranadaActive, not recruiting
-
Advanced Pain and Rehab SpecialistsHemp synergisticsNot yet recruitingInsomnia | Anxiety | Opioid Use | Pain, Chronic | CBDUnited States
-
University of Texas at AustinSuspendedPost Traumatic Stress DisorderUnited States
-
Pure GreenRecruitingOsteoarthritis, KneeUnited States
-
University of CalgaryNot yet recruitingChronic Migraine
-
Wake Forest University Health SciencesNational Institute on Drug Abuse (NIDA); University of North Carolina, Chapel... and other collaboratorsCompleted
-
Canopy Growth CorporationNM Clinical Research & Osteoporosis Center, Inc.Terminated